POLYPEPTIDES EXHIBITING HUMAN GRANULOCYTE MACROPHAGE AND EOSINOPHIL CELLULAR GROWTH FACTOR ACTIVITY

• Main Authors: RENNICK, DONNA M, ARAI, KENICHI, LEE, FRANK D, YOKOTA, TAKASHI
• Format: Patent
• Language: English; Korean
• Published: 15.05.1992
• Edition: 5
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

Plasmid vectors that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting human granulocyte/macrophage colony stimulating factor activity, including eosinophil growth factor activity. One of these polypeptides is about 144 amino acids in length, including a potential leader sequence. The cDNA is derived from messenger RNA isolated from a human cell source after activation with concanavalin A. The cDNA was cloned by incorporation into a plasmid vector, which was then transformed into E. coli. The plasmid vector also contained DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as monkey COS-7 cells.